Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jan;27(1):321-336.
doi: 10.1007/s10741-020-09980-6.

The effect of nutraceuticals on multiple signaling pathways in cardiac fibrosis injury and repair

Affiliations
Review

The effect of nutraceuticals on multiple signaling pathways in cardiac fibrosis injury and repair

Parinaz Zivarpour et al. Heart Fail Rev. 2022 Jan.

Abstract

Cardiac fibrosis is one of the most common pathological conditions caused by different heart diseases, including myocardial infarction and diabetic cardiomyopathy. Cardiovascular disease is one of the major causes of mortality worldwide. Cardiac fibrosis is caused by different processes, including inflammatory reactions and oxidative stress. The process of fibrosis begins by changing the balance between production and destruction of extracellular matrix components and stimulating the proliferation and differentiation of cardiac fibroblasts. Many studies have focused on finding drugs with less adverse effects for the treatment of cardiovascular disease. Some studies show that nutraceuticals are effective in preventing and treating diseases, including cardiovascular disease, and that they can reduce the risk. However, big clinical studies to prove the therapeutic properties of all these substances and their adverse effects are lacking so far. Therefore, in this review, we tried to summarize the knowledge on pathways and mechanisms of several nutraceuticals which have shown their usefulness in the prevention of cardiac fibrosis.

Keywords: Cardiac fibrosis; Cardiovascular disease; Inflammatory markers; Nutraceuticals; Oxidative stress.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Gu HP, Lin S, Xu M, Yu HY, du XJ, Zhang YY, Yuan G, Gao W (2012) Up-regulating relaxin expression by G-quadruplex interactive ligand to achieve antifibrotic action. Endocrinology 153:3692–3700 - PubMed
    1. Yu C-M, Tipoe GL, Lai KW-H, Lau C-P (2001) Effects of combination of angiotensin-converting enzyme inhibitor and angiotensin receptor antagonist on inflammatory cellular infiltration and myocardial interstitial fibrosis after acute myocardial infarction. J Am Coll Cardiol 38:1207–1215 - PubMed
    1. Querejeta R, López B, González A et al (2004) Increased collagen type I synthesis in patients with heart failure of hypertensive origin: relation to myocardial fibrosis. Circulation 110:1263–1268 - PubMed
    1. Li L, Zhao Q, Kong W (2018) Extracellular matrix remodeling and cardiac fibrosis. Matrix Biol 68-69:490–506 - PubMed
    1. Park S, Nguyen NB, Pezhouman A, Ardehali R (2019) Cardiac fibrosis: potential therapeutic targets. Transl Res 209:121–137 - PubMed - PMC

LinkOut - more resources